SCHEMBL11955705

SCHEMBL11955705

Cc1ccc2c(c1)-c1nc(N/C=N\O)sc1CC2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.50
TP53 P04637 6/20 0.50
POLB P06746 2/20 0.44
ALDH1A1 P00352 6/20 0.43
KDM4E B2RXH2 5/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
HPGD P15428 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
RXFP1 Q9HBX9 1/20 0.42
ADORA1 P30542 1/20 0.41
LMNA P02545 2/20 0.41
CYP2D6 P10635 1/20 0.41
PKM P14618 1/20 0.41
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6886816 0.85 MAPT (0.60) MAPTTP53POLBALDH1A1KDM4E
SCHEMBL11895247 0.85 MAPT (0.60) MAPTTP53POLBALDH1A1KDM4E
SCHEMBL11955706 0.72 ADORA1 (0.74) MAPTALDH1A1KDM4EADORA1MPI
SCHEMBL11955704 0.70 MAPT (0.48) MAPTTP53ALDH1A1KDM4EHPGD
SCHEMBL12678086 0.64 ADORA1 (0.48) MAPTTP53POLBALDH1A1KDM4E
SCHEMBL353940 0.60 HTT (0.49) MAPTTP53POLBKDM4EHPGD
SCHEMBL353939 0.60 HTT (0.49) MAPTTP53POLBKDM4EHPGD
Iodide SCHEMBL3994600 0.59 ADORA1 (1.00) ADORA1FBP1
SCHEMBL1746834 0.59 ALOX5 (0.77) MAPTTP53POLBALDH1A1KDM4E
SCHEMBL15096855 0.59 MAPT (0.44) MAPTTP53POLBALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120196852-A1 INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS THE JOHNS HOPKINS UNIVERSITY (US) 2012-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196852-A1 INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS METAP1, METAP2, ENPEP MAPT 1551/4885TP53 2574/4885POLB 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.